Your Search Returned 339 tagged news reports
There's an awful lot of chemical biology to be done in the kinase field, far more than any one organization could take on, and the more sets of eyes (and cerebral cortices) that are on these problems, the better. So far, there have been about 80
The rejection follows the company's previously dismissed proposal to install wind turbines at the facility. The company, which has accepted the decision, is working with Marine Scotland to evaluate the bladeless tidal turbines feasibility, reports
Breo Ellipta is expected to be available in the US during the third quarter of 2013. FDA approval triggers $30m milestone payment to GSK from Theravance.
All sectors have their own mood music, unobtrusive much of the time, but occasionally brought to startling effect into the foreground, dominating all else. The pharmaceutical industry is no different, and at present there is one insistent theme:
Both the organizations will work together in a different way to share expertise, resources, reach, and influence in fighting few main causes of childhood deaths. Save the Children, UK, chief executive Justin Forsyth said, "In the past Save the
The new online system available on gsk.com enables researchers to access the detailed trial data that helps with more scientific understanding and patient care improvement. Researchers should provide a scientific protocol with an assurance to publish
The funding will move the early-stage research to the next level, to find new medicines for diseases such as TB, malaria, Leishmaniasis and sleeping sickness. Scientists across the globe will work in collaboration with GSK drug discovery experts at
Theravance, in addition to GSK's medicines FF monotherapy and anti-IL5 MAb.
Impax ends Parkinson's deal with GlaxoSmithKline Impax Laboratories Inc. ended a deal to develop and sell a treatment for Parkinson's disease with GlaxoSmithKline. GSK) on IPX066, an extended release formulation of carbidopa-levidopa, through its
A leading academic and clinician has, however, questioned their assertions and challenged them over how closely their promises would manifest into action. MPs on the House of Commons Science and Technology Committee held an evidence session on 22